Hybio Pharmaceutical Co., Ltd.
300199
Rang in Aktien
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Aktienkurs
$3.69
Marktkapitalisierung
$3.11B
Veränderung (1 Tag)
-7.75%
Veränderung (1 Jahr)
21.56%
Land
CN
Handel Hybio Pharmaceutical Co., Ltd. (300199)
Kategorie
Healthcare
Operative Marge für Hybio Pharmaceutical Co., Ltd. (300199)
Operative Marge zum October 2026 TTM: 17.45%
Laut den neuesten Finanzberichten und dem Aktienkurs von Hybio Pharmaceutical Co., Ltd. beträgt die aktuelle operative Marge (TTM) 17.45%. Am Ende des Jahres 2024 lag die operative Marge bei -27.34%.
Historie der operativen Marge von Hybio Pharmaceutical Co., Ltd. von 2007 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 17.45% | 144.06% |
| 2025 | 7.15% | -126.15% |
| 2024 | -27.34% | -76.76% |
| 2023 | -117.65% | 123.46% |
| 2022 | -52.65% | -1,091.53% |
| 2021 | 5.31% | -106.67% |
| 2020 | -79.58% | -46.01% |
| 2019 | -147.40% | 481.92% |
| 2018 | -25.33% | -189.06% |
| 2017 | 28.44% | -12.49% |
| 2016 | 32.50% | -24.10% |
| 2015 | 42.82% | -2.04% |
| 2014 | 43.71% | -7.37% |
| 2013 | 47.19% | 27.47% |
| 2012 | 37.02% | -5.54% |
| 2011 | 39.19% | -8.24% |
| 2010 | 42.71% | -0.58% |
| 2009 | 42.96% | 32.92% |
| 2008 | 32.32% | 5.00% |
| 2007 | 30.78% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 19.41% | -98.89% |
DE
|
|
| 19.68% | -98.87% |
DE
|
|
| 10.52% | -99.40% |
JP
|
|
| 17.08% | -99.02% |
CH
|
|
| 22.93% | -98.69% |
IN
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.